Short Interest in Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Increases By 29.8%

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 85,580 shares, a growth of 29.8% from the January 15th total of 65,924 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 69,840 shares, the days-to-cover ratio is currently 1.2 days. Based on an average daily trading volume, of 69,840 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.0% of the shares of the company are sold short.

Sandoz Group Price Performance

Shares of Sandoz Group stock opened at $85.73 on Tuesday. Sandoz Group has a 52-week low of $35.61 and a 52-week high of $86.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.82 and a current ratio of 1.29. The stock’s 50-day simple moving average is $76.77 and its 200 day simple moving average is $67.81.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.